GLP-1 medications work. That is no longer debatable. What is increasingly debatable is whether the weight they help you lose is the right kind of weight.
When you lose weight on semaglutide or tirzepatide, you are not losing only fat. Clinical trial data consistently shows that roughly 25–40% of total weight lost on these medications is lean body mass — a category that includes muscle, organ tissue, bone mineral content, and water. For someone who loses 50 pounds on tirzepatide, that could mean 12–20 pounds of lean tissue gone alongside the fat.
For healthy, younger adults with significant fat reserves, this lean mass loss may not be clinically meaningful. But for older adults, patients with limited muscle reserves, or anyone at risk of sarcopenic obesity — a condition where low muscle mass coexists with high body fat — the implications are serious. Muscle loss affects mobility, fall risk, metabolic rate, and long-term functional independence.
What the Data Shows
The Clinical Trial Picture
A systematic review and network meta-analysis published in late 2024 analyzed body composition data from multiple GLP-1 medication trials. The findings confirmed that while higher-potency GLP-1 medications like tirzepatide (15 mg) and semaglutide (2.4 mg) produced the greatest total weight loss and fat mass reduction, they were also among the least effective at preserving lean mass.
The percentage of lean mass relative to total body weight remained roughly constant — meaning the body lost lean tissue and fat tissue in approximately the same ratio. This is consistent with what happens during caloric restriction in general: the body does not selectively protect muscle when energy intake drops sharply.
| Medication | Lean Mass Loss Ratio | Total Weight Loss |
|---|---|---|
| Semaglutide 2.4 mg | ~39% of weight lost | ~15–17% |
| Tirzepatide 15 mg | ~33–38% of weight lost | ~20–22% |
| Liraglutide 3.0 mg | ~30–35% of weight lost | ~8–10% |
The Preprint That Raised Alarms
In April 2026, a large-scale preprint analyzing EHR-linked body composition data from 670,422 first-episode GLP-1 users (456,742 on semaglutide, 213,680 on tirzepatide) added an important wrinkle to this picture.
The analysis found that tirzepatide was associated with greater relative lean body mass loss than semaglutide at every measured time point over 12 months, with excess LBM losses of 1.1%, 1.5%, 1.3%, and 2.0% at 3, 6, 9, and 12 months respectively.
Perhaps more concerning: a "depletive metabotype" — defined as greater than 20% total body weight loss combined with greater than 5% lean body mass loss — was significantly more common with tirzepatide (10.3% of patients) than semaglutide (6.7%).
The study also found that patients with baseline musculoskeletal pain (especially cervical and knee pain) were significantly more vulnerable to lean tissue depletion, likely because mobility limitations prevented them from engaging in the resistance training that helps preserve muscle during weight loss.
Important context: This is a preprint — it has not yet completed peer review. The data is from real-world EHR records, which introduces confounders not present in controlled trials. The proportional lean mass loss between the two drugs in controlled head-to-head trials (SURMOUNT-5) was similar. The preprint's finding of greater absolute lean mass loss with tirzepatide may primarily reflect the fact that tirzepatide produces more total weight loss.
Why This Matters
Muscle is not just for aesthetics. It is the body's primary metabolic engine. Each pound of muscle burns approximately 6–7 calories per day at rest, compared to 2–3 calories per pound of fat. Losing muscle while losing weight has three practical consequences:
Metabolic adaptation: As muscle mass decreases, your resting metabolic rate drops. This means you burn fewer calories at rest, making it harder to maintain weight loss and easier to regain weight if you stop the medication. This is one reason why weight regain after GLP-1 discontinuation is so common.
Functional decline: For older adults especially, muscle loss affects the ability to perform daily activities, maintain balance, and prevent falls. Sarcopenic obesity — high body fat with low muscle mass — is associated with worse health outcomes than obesity alone.
Body composition paradox: You can reach a lower number on the scale while still carrying a higher percentage of body fat than before, because the muscle loss changes your ratio of fat to lean tissue. This is not the outcome anyone wants from weight loss treatment.
What You Can Do About It
The lean mass problem is real, but it is not inevitable. Research consistently shows that patients who combine GLP-1 therapy with specific lifestyle interventions can significantly reduce or even prevent lean mass loss. A case series from Texas Tech published in 2025 documented patients who maintained or even increased lean tissue during GLP-1 treatment through structured nutrition and exercise.
Protein: The Non-Negotiable
Protein intake is the single most important dietary factor for preserving lean mass during weight loss. GLP-1 medications suppress appetite, which reduces total caloric intake — but if protein intake drops proportionally, muscle protein synthesis suffers.
The evidence-based target: 0.8 to 1.0 grams of protein per pound of lean body mass per day, or approximately 1.2 to 1.6 grams per kilogram of total body weight. For a 200-pound person, that is roughly 100–130 grams of protein daily. This needs to be prioritized in your reduced-calorie diet, meaning protein should be the first thing on your plate at every meal.
Resistance Training: The Other Non-Negotiable
Resistance training (weightlifting, resistance bands, bodyweight exercises) is the primary stimulus that tells your body to preserve muscle during caloric deficit. Without this stimulus, the body has no metabolic reason to maintain muscle it is not using.
The minimum effective protocol: 2–3 sessions per week, targeting all major muscle groups, with progressive overload (gradually increasing weight or resistance over time). This does not require a gym membership — bodyweight exercises and resistance bands can be sufficient, especially for beginners.
Adequate Sleep and Recovery
Muscle protein synthesis happens primarily during sleep. Patients on GLP-1 medications who are in a caloric deficit need adequate sleep (7–9 hours) to support muscle recovery and minimize the catabolic effects of reduced caloric intake.
The Pipeline: Medications Designed to Spare Muscle
The pharmaceutical industry is aware of the lean mass problem and is actively developing solutions. Bimagrumab, an antibody that blocks the myostatin/activin pathway, has shown in combination with semaglutide the ability to preserve over 90% of weight loss as pure fat loss. Pemvidutide, a GLP-1/glucagon dual agonist, has shown a lower lean mass loss ratio in early data, possibly because the glucagon component preferentially directs the body to burn fat rather than muscle.
These are not yet available commercially, but they signal that next-generation obesity treatments will increasingly be designed with body composition in mind — not just the number on the scale.
Find a Provider That Focuses on Outcomes
The best GLP-1 providers include nutritional guidance and exercise recommendations alongside the prescription. Compare providers who treat the whole patient, not just the scale.
Compare Providers